rs34640941
Positions:
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_000051.4(ATM):c.4424A>G(p.Tyr1475Cys) variant causes a missense change. The variant allele was found at a frequency of 0.000974 in 1,612,680 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00054 ( 1 hom., cov: 32)
Exomes 𝑓: 0.0010 ( 0 hom. )
Consequence
ATM
NM_000051.4 missense
NM_000051.4 missense
Scores
4
15
Clinical Significance
Conservation
PhyloP100: 3.91
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -3 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.07898763).
BP6
Variant 11-108289789-A-G is Benign according to our data. Variant chr11-108289789-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 127392.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=11, Benign=2, Uncertain_significance=9}. Variant chr11-108289789-A-G is described in Lovd as [Likely_benign].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.4424A>G | p.Tyr1475Cys | missense_variant | 29/63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATM | ENST00000675843.1 | c.4424A>G | p.Tyr1475Cys | missense_variant | 29/63 | NM_000051.4 | ENSP00000501606 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000539 AC: 82AN: 152216Hom.: 1 Cov.: 32
GnomAD3 genomes
AF:
AC:
82
AN:
152216
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000600 AC: 150AN: 250206Hom.: 0 AF XY: 0.000577 AC XY: 78AN XY: 135270
GnomAD3 exomes
AF:
AC:
150
AN:
250206
Hom.:
AF XY:
AC XY:
78
AN XY:
135270
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00102 AC: 1489AN: 1460346Hom.: 0 Cov.: 31 AF XY: 0.000953 AC XY: 692AN XY: 726494
GnomAD4 exome
AF:
AC:
1489
AN:
1460346
Hom.:
Cov.:
31
AF XY:
AC XY:
692
AN XY:
726494
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000538 AC: 82AN: 152334Hom.: 1 Cov.: 32 AF XY: 0.000403 AC XY: 30AN XY: 74496
GnomAD4 genome
AF:
AC:
82
AN:
152334
Hom.:
Cov.:
32
AF XY:
AC XY:
30
AN XY:
74496
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
5
ALSPAC
AF:
AC:
7
ESP6500AA
AF:
AC:
3
ESP6500EA
AF:
AC:
7
ExAC
AF:
AC:
56
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:10Benign:16
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Ataxia-telangiectasia syndrome Uncertain:4Benign:3
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Nov 15, 2018 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | May 03, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | May 18, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Benign, criteria provided, single submitter | clinical testing | Mendelics | Aug 22, 2023 | - - |
not specified Uncertain:1Benign:4
Likely benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Mar 19, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Jan 04, 2018 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 05, 2024 | Variant summary: ATM c.4424A>G (p.Tyr1475Cys) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00098 in 1614758 control chromosomes, predominantly at a frequency of 0.0012 within the Non-Finnish European subpopulation in the gnomAD (v4.0.0) database, including 1 homozygotes. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is higher than the estimated maximal expected allele frequency for a pathogenic variant in ATM causing Breast Cancer phenotype (0.001), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. In addition, this variant has been reported in 16/7325 European American women, who are older than age 70 and cancer free (in the FLOSSIES database). Multiple publications cite the variant in sequencing studies of affected individuals with varying tumor phenotypes, including breast-, pancreatic- and prostate cancer, lymphoma and Lynch Syndrome, although with limited information (i.e. lack of co-occurrence and cosegregation data). These reports therefore do not provide unequivocal conclusions about association of the variant with Breast Cancer/Ataxia-Telangiectasia. Co-occurrences with other pathogenic variant(s) have been reported (MSH2 c.1861C>T, p.Arg621X, internal testing), providing supporting evidence for a benign role. To our knowledge, no publication reported experimental evidence evaluating an impact on protein function. The following publications have been ascertained in the context of this evaluation (PMID: 17344846, 23555315, 25980754, 16167060, 19781682, 17640065, 20305132, 17333338, 16832357, 16914028, 12697903, 25479140, 12935922, 25862857, 26787654, 26898890, 26976419, 23369113, 27978560, 28652578, 27782108). ClinVar contains an entry for this variant (Variation ID: 127392). Based on the evidence outlined above, the variant was classified as likely benign. - |
Likely benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Jul 31, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Dec 30, 2020 | DNA sequence analysis of the ATM gene demonstrated a sequence change, c.4424A>G, in exon 29 that results in an amino acid change, p.Tyr1475Cys. This sequence change has been described in the gnomAD database with a frequency of 0.1% in the Finnish sub-population (dbSNP rs34640941). The p.Tyr1475Cys change has been identified in a female with breast cancer (PMID: 26976419) and in an individual with colon cancer (PMID: 27978560). The p.Tyr1475Cys change affects a poorly conserved amino acid residue located in a domain of the ATM protein that is not known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Tyr1475Cys substitution. Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Tyr1475Cys change remains unknown at this time. - |
Hereditary cancer-predisposing syndrome Uncertain:1Benign:4
Likely benign, no assertion criteria provided | clinical testing | True Health Diagnostics | Apr 26, 2018 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 02, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Dec 29, 2014 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C. | Jan 20, 2022 | - - |
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Jun 16, 2021 | - - |
not provided Benign:3
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Nov 27, 2019 | - - |
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 04, 2017 | The p.Tyr1475Cys variant (rs34640941) has not been reported association with ataxia telangiectasia in the medical literature or gene specific variation databases but has been reported to ClinVar (Variation ID: 127392). However, the p.Tyr1475Cys variant has been identified in numerous cancer sequencing cohorts in both case and controls (Fang 2003, Meier 2005, Sipahimalani 2007, Sommer 2003, Tavtigian 2009, Tommiska 2006 and Yurgelun 2015). In a large meta-analysis of breast cancer studies, Tavtigian et al. identified the p.Tyr1475Cys variant in 1/4112 breast cancer cases and 6/2399 controls. Based on these observations the p.Tyr1475Cys variant is likely to be benign. - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | ATM: BP4 - |
Familial cancer of breast Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Division of Medical Genetics, University of Washington | Jan 03, 2019 | This variant has been reported in individuals with breast cancer (Tung 2016, Tommiska 2006), as well as control populations (Hirsch 2008, Sommer 2003). The c.4424A>G variant has an overall allele frequency of 0.0006 in the Genome Aggregation Database (gnomad.broadinstitute.org). In silico analyses indicate this is an evolutionarily conserved residue. Thus, it is unknown at this time whether this variant increases cancer risk. - |
Likely benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | May 17, 2024 | This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. - |
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Jul 30, 2021 | - - |
Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago | Mar 30, 2021 | ATM NM_000051.3 exon 29 p.Tyr1475Cys (c.4424A>G): This variant has been reported in the literature as germline in at least 6 individuals with various types of cancer (breast, colon, lymphoma) (Sipahimalani 2007 PMID:17640065, Tavtigian 2009 PMID:19781682, Yurgelun 2015 PMID:19781682, Tung 2016 PMID:26976419, Pearlman 2017 PMID:27978560). However, this variant has also been identified in controls (Tavtigian 2009 PMID:19781682) and is present in 0.1% (26/25072) of Finnish alleles in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/11-108160516-A-G?dataset=gnomad_r2_1). This variant is present in ClinVar (Variation ID:127392). Evolutionary conservation and computational predictive tools for this variant are unclear. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. - |
Malignant tumor of breast Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The ATM p.Tyr1475Cys variant was identified in 4 of 1802 proband chromosomes (frequency: 0.002) from African-American, American, Finnish, Dutch and German individuals or families with breast cancer (unselected for history) or childhood acute lymphocytic leukemia; and was present in 1 of 856 control chromosomes (frequency: 0.001) from healthy individuals (Hirsch 2008, Tung 2016, Tommiska 2006, Meier 2005). The variant was also identified in the following databases: dbSNP (ID: rs34640941) “With Uncertain significance allele”, ClinVar (classified with conflicting interpretations of pathogenicity, sumbitters: uncertain significance by GeneDx; likely benign by Invitae and Ambry Genetics), Clinvitae (3x), Cosmic (1x in a diffuse large b cell lymphoma) and was not identified in the COGR, MutDB, LOVD 3.0 or ATM-LOVD databases. The variant was identified in control databases in 152 of 276060 chromosomes at a frequency of 0.0006 increasing the likelihood this could be a low frequency variant (Genome Aggregation Consortium Feb 27, 2017). It was identified in the following populations: African in 5 of 23840 chromosomes (frequency: 0002), Other in 4 of 6426 chromosomes (frequency: 0006), Latino in 10 of 34336 chromosomes (frequency: 0003), European Non-Finnish in 109 of 126152 chromosomes (frequency: 0.0009), and European Finnish in 24 of 25740 chromosomes (frequency: 005). The p.Tyr1475 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
ATM-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 11, 2021 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;.;D
M_CAP
Benign
D
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
M;M;.
MutationTaster
Benign
D;D
PrimateAI
Benign
T
PROVEAN
Uncertain
D;D;.
REVEL
Uncertain
Sift
Benign
T;T;.
Sift4G
Benign
T;T;D
Polyphen
P;P;.
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at